Country Report: France
Pharmaceutical Executive
After several years of losing pace to many of its European peers when it comes to pharma production and R&D, France’s life sciences market, sparked by a renewed spirit of reform, is now squarely back on the radar of the international investor community.
Better Together
When Emmanuel Macron’s “La République En Marche (LaREM)” movement defied the odds to capture the presidency and national assembly back in May 2017, it readily became apparent that the pro-business administration would be supporting innovative pharma and attempting to reinvigorate the country’s competitiveness and global reputation for pioneering breakthrough medical science.
“We consider life sciences both as a dynamo of technological advancement and host of some of the great emerging high value-added industries of the future … It is precisely for this reason that we have elevated the sector as one of the centerpieces of our new national industrial strategy,” affirms Minister of Economy and Finance, Bruno Le Maire.
Many industry actors appear suitably charmed. “After several years in which French pharmaceutical production and R&D had frankly been losing pace relative to many of our peer markets, I and my members salute the renewed spirit of reform that drives and infuses the incumbent government,” declares Jean-Luc Bélingard, president of the French Federation of the Health Industry (FEFIS) and former CEO of French IVD icon bioMérieux.
Such sentiment is hardly unfounded. France’s USD 65 billion life sciences market is now squarely back on the radar of the international investor community with multinationals like GlaxoSmithKline, Novartis, Merck, and Aspen all proceeding with big-ticket investments and Ernst & Young calculating that overall FDI has increased 31 percent within the space of only a year.
To view the full article on France's life sciences and medical technology markets, produced by Focus Reports and featured in Pharm Exec's June 2019 issue, click
here(cycle down to page 38).
To preview and purchase other in-depth global Phama Reports, highlighting several countries and emerging markets, please visit www.industrymatter.com/reports
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer Discontinues Development of Danuglipron for Chronic Weight Management
April 15th 2025Despite meeting key pharmacokinetic goals, a potential case of drug-induced liver injury led Pfizer to conclude that danuglipron’s risk-benefit profile did not support further development for chronic weight management.
